论文部分内容阅读
目的 评价浙江省2017年脊髓灰质炎 (脊灰) 疫苗接种安全性.方法 收集全国疑似预防接种异常反应 (AEFI) 监测系统中2017年报告的脊灰疫苗AEFI个案, 采用描述性流行病学方法进行分析.结果 浙江省2017年共报告脊灰疫苗AEFI个案1 402例, 报告发生率为44.32/10万剂;其中Sabin株灭活脊灰疫苗 (Sabin-IPV) 、Salk株灭活脊灰疫苗 (Salk-IPV) 、无细胞百白破-灭活脊灰-流感嗜血杆菌联合疫苗 (DTaP-IPV/Hib) 、二价脊灰减毒疫苗 (bOPV) AEFI发生率分别为17.90/10万剂、17.97/10万剂、275.32/10万剂、8.14/10万剂.在所有AEFI中, 一般反应、异常反应分别占93.15％、5.28％;在异常反应中过敏性皮疹占74.32％.结论 浙江省脊灰疫苗的预防接种安全性良好.“,”Objective To evaluate immunization saf ety of polio vaccines in Zhejiang province in 2017. Methods We used the National Adverse Event Following Immunization (AEFI) Inf ormation System to obtain data on polio vaccination AEFIs reported in 2017 and conducted descriptive epidemiological analyses. Results A total of 1 402 AEFI cases associated with polio vaccines were reported in Zhejiang in 2017, yielding an incidence of 44.32 per100 000 doses administered. AEFI incidence rates for Sabin strain inactivated poliovirus vaccine (Sabin-IPV), Salk strain inactivated poliovirus vaccine (Salk-IPV), diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenza type b combined vaccine (DTaP-IPV/Hib), and bivalent oral poliovirus vaccine (bOPV) were17.90, 17.97, 275.32, and 8.14 per 100 000 doses, respectively. Among all AEFI reports, common and rare vaccine reactions accounted for 93.15％ and 5.28％, respectively; 74.32％ of rare vaccine reactions were anaphylactic rashes.Conclusions Polio vaccines had a good safety profile in Zhejiang province.